Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 12, 2004, Pages 2258-2263

  Keogh, Louise A ^a   Southey, Melissa C ^b   Maskiell, Judi ^c   Young, Mary Anne ^d   Gaff, Clara L ^e   Kirk, Judy ^f   Tucker, Katherine M ^g   Rosenthal, Doreen ^a   McCredie, Margaret R E ^h   Giles, Graham G ⁱ   Hopper, John L ^b,c  

^a Key Centre for Women's Health in Society   (Australia)

^b Cancer Genomics and Genetics   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ATTITUDE; BRCA2 GENE; BREAST CANCER; CANCER CENTER; CASE CONTROL STUDY; FAMILY HISTORY; FAMILY STUDY; FEMALE; GENDER; GENE MUTATION; GENETIC INFORMATION; GENETIC SCREENING; GERM LINE; GOVERNMENT; HEALTH CARE UTILIZATION; HUMAN; INFORMATION SERVICE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; ONCOGENE; OVARY CANCER; POPULATION RESEARCH; PRIORITY JOURNAL;

EMPIRICAL APPROACH; GENETICS AND REPRODUCTION;

ADULT; AGE OF ONSET; ATTITUDE TO HEALTH; AUSTRALIA; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DECISION MAKING; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; NEOPLASM INVASIVENESS; PATIENT COMPLIANCE; PEDIGREE; TRUTH DISCLOSURE;

EID: 19944429733     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
2. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2. N Engl J Med 2002;346:1616-22.
3. Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust 2003;178:77-81.
4. Phillips KA. Current perspectives on BRCA1- and BRCA2-associated breast cancers. Intern Med J 2001;31:349-56.
5. Ulrich CM, Kristal AR, White E, Hunt JR, Durfy SJ, Potter JD. Genetic testing for cancer risk: a population survey on attitudes and intention. Community Genet 1998;1:213-22.
6. Andrykowski MA, Munn RK, Studts JL. Interest in learning of personal genetic risk for cancer: a general population survey. Prev Med 1996;25:527-36.
7. Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W. Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am J Med Genet 2001;99:99-110.
8. Welkenhuysen M, Evers-Kiebooms G, Decruyenaere M, Claes E, Denayer L. A community based study on intentions regarding predictive testing for hereditary breast cancer. J Med Genet 2001;38:540-7.
9. Armstrong K, Weber B, Ubel P, Guerra C, Schwartz JS. Interest in BRCA1/2 testing in a primary care population. Prev Med 2002;34:590-5.
10. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997;68:43-9.
11. Gwyn K, Vernon SW, Conoley PM. Intention to pursue genetic testing for breast cancer among women due for screening mammography. Cancer Epidemiol Biomarkers Prev 2003;12:96-102.
12. Chaliki H, Loader S, Levenkron J, Logan-Young W. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 1995;85:1133-5.
13. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 1995;57:385-92.
14. Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 1999;8:369-75.
15. Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994;12:843-50.
16. Jacobsen PB, Valdimarsdottir HB, Brown KL, Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 1997;59:459-66.
17. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4:169-73.
18. Geller G, Doksum T, Bernhardt BA, Metz SA. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions. Cancer Epidemiol Biomarkers Prev 1999;8:377-83.
19. Lee S-C, Bernhardt BA, Helzsouer KJ. Utilization of BRCA1/2 genetic testing in the clinical setting. Cancer 2002;94:1876-85.
20. Julian-Reynier C, Sobol H, Sevilla C, Nogues C, Bourret P, and The French Cancer Genetic Network. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. Psychooncology 2000;9:504-10.
21. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996;275:1885-92.
22. Biesecker BB, Ishibe N, Hadley DW, et al. Psychosocial factors predicting BRC41/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000;93:257-63.
23. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000;355:2015-20.
24. National Health and Medical Research Council. National statement on ethical conduct in research involving humans. Canberra: National Health and Medical Research Council; 1999.
25. McCredie MR, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control 1998;9:189-98.
26. Hopper JL, Chenevix-Trench G, Jolley D, Dite G, Jenkins MA. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Cooperative Family Registry for Breast Cancer Family Studies (CFRBCS). J Natl Cancer Inst Monogr 1999;26:95-100.
27. Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germ line mutations. J Natl Cancer Inst 2003;95:448-57.
28. Mazoyer S, Dunning AM, Serova O, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
29. 2-terminal BRCA1 RING finger domain. J Biol Chem 1998;273:7795-9.
30. National Health and Medical Research Council. Familial aspects of cancer: a guide to clinical practice. Clinical practice guidelines. Canberra: National Health and Medical Research Council; 1999.
31. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
32. iSource National Breast Cancer Centre. Advice about familial aspects of breast cancer and ovarian cancer: a guide for health professionals. Sydney: NHMRC National Breast Cancer Centre; 2000.